Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

Thumbnail Image
Download
Name

Bear5.pdf

Size

204.66 KB

Format

Adobe PDF

Checksum (MD5)

7f74286c47efca816483d1e93a06613b

Author(s)
Erickson, Craig A.
•
Veenstra-Vanderweele, Jeremy M.
•
Melmed, Raun D.
•
McCracken, James T.
•
Ginsberg, Lawrence D.
•
Sikich, Linmarie
•
Scahill, Lawrence
•
Cherubini, Maryann
•
Zarevics, Peter
•
Walton-Bowen, Karen
more
Date Issued
November 2013
Journal
Journal of Autism and Developmental Disorders
Publisher
Springer-Verlag
Citation
Erickson, Craig A., Jeremy M. Veenstra-Vanderweele, Raun D. Melmed, James T. McCracken, Lawrence D. Ginsberg, Linmarie Sikich, Lawrence Scahill, et al. “STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study.” Journal of Autism and Developmental Disorders 44, no. 4 (November 23, 2013): 958–964.
Version
Author's final manuscript
Abstract
STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder—Not Otherwise Specified, and a score ≥17 on the Aberrant Behavior Checklist (ABC)—Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted.
MIT Department
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Picower Institute for Learning and Memory
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
http://creativecommons.org/licenses/by-nc-sa/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/95779
DOI of Published Version
https://doi.org/10.1007/s10803-013-1963-z
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.